U.S. markets close in 6 hours 4 minutes
  • S&P 500

    3,875.07
    +63.92 (+1.68%)
     
  • Dow 30

    31,471.69
    +539.32 (+1.74%)
     
  • Nasdaq

    13,413.38
    +221.03 (+1.68%)
     
  • Russell 2000

    2,249.42
    +48.37 (+2.20%)
     
  • Crude Oil

    61.64
    +0.14 (+0.23%)
     
  • Gold

    1,736.50
    +7.70 (+0.45%)
     
  • Silver

    26.95
    +0.51 (+1.93%)
     
  • EUR/USD

    1.2048
    -0.0039 (-0.33%)
     
  • 10-Yr Bond

    1.4190
    -0.0410 (-2.81%)
     
  • GBP/USD

    1.3922
    -0.0000 (-0.00%)
     
  • USD/JPY

    106.6320
    +0.1300 (+0.12%)
     
  • BTC-USD

    48,167.00
    +3,466.03 (+7.75%)
     
  • CMC Crypto 200

    966.70
    +38.47 (+4.14%)
     
  • FTSE 100

    6,567.45
    +84.02 (+1.30%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

Recap: Invitae Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Invitae (NYSE:NVTA) fell in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were unchanged 0.00% over the past year to ($0.63), which missed the estimate of ($0.55).

Revenue of $100,431,000 rose by 51.51% from the same period last year, which beat the estimate of $98,400,000.

Outlook

 

Invitae Sees FY2021 Revs Exceeding $450M

Conference Call Details

Date: Feb 17, 2021

View more earnings on NVTA

Time: 04:30 PM

ET Webcast URL: https://www.directeventreg.com/der/toRegistration.action

Recent Stock Performance

Company's 52-week high was at $61.59

Company's 52-week low was at $7.42

Price action over last quarter: Up 6.93%

Company Description

Invitae Corp operates as a genetic information company in diagnostic and research industry. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.